证券代码：688426 证券简称：康为世纪 公告编号：2025-004 江苏康为世纪生物科技股份有限公司 2024 年年度业绩预亏公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2024 年 1 月 1 日至 2024 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，江苏康为世纪生物科技股份有限公司(以下简称"公 司")预计 2024 年年度实现归属于母公司所有者的净利润与上年同期相比将出现 亏损，实现归属于母公司所有者的净利润-14,200.00 万元到-17,000.00 万元，与上 年同期相比下降 68.23%至 101.40%。 2、归属于母公司所有者扣除非经常性损益后的净利润-16,600.00 万元到- 19,400.00 万元，与上年同期相比下降 38.92%至 62.35%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 （一）利润总额-9,298.28 万元；归属于母公司所有者的净利润-8,440.95 万 元；归属于母公 ...

Revenue and Profit Performance - Revenue for the third quarter was RMB 31.14 million, a 4.15% increase year-over-year, while year-to-date revenue was RMB 98.28 million, a 35.11% decrease compared to the same period last year[2] - Total operating revenue for the first three quarters of 2024 was RMB 98.28 million, a decrease of 35.1% compared to RMB 151.45 million in the same period of 2023[17] - Net profit attributable to shareholders for the year-to-date was a loss of RMB 45.59 million, a 77.60% decrease year-over-year, and a total loss of RMB 95.65 million year-to-date, a 169.09% decrease[2] - Net profit for the first three quarters of 2024 was a loss of RMB 95.91 million, compared to a loss of RMB 30.04 million in the same period of 2023[18] - The decrease in revenue was primarily due to slow growth in traditional business and lower-than-expected sales of new products[7] - The decrease in net profit was mainly due to a decline in revenue and an increase in fixed costs[7] R&D Investment - R&D investment for the third quarter was RMB 26.03 million, a 20.52% increase year-over-year, and year-to-date R&D investment was RMB 72.05 million, a 13.62% increase[2] - R&D investment as a percentage of revenue for the third quarter was 83.60%, an increase of 11.36 percentage points year-over-year, and year-to-date R&D investment as a percentage of revenue was 73.31%, an increase of 10.29 percentage points[3] - R&D expenses for the first three quarters of 2024 increased to RMB 72.05 million, up 13.6% from RMB 63.41 million in the same period of 2023[17] Financial Position and Assets - Total assets at the end of the reporting period were RMB 1.67 billion, an 8.33% decrease compared to the end of the previous year[3] - Total assets as of Q3 2024 were RMB 1.67 billion, a decrease of 8.3% from RMB 1.82 billion in the same period of 2023[16] - Total liabilities as of Q3 2024 were RMB 120.91 million, a decrease of 15.2% from RMB 142.67 million in the same period of 2023[16] - Total equity attributable to the parent company as of Q3 2024 was RMB 1.53 billion, a decrease of 7.8% from RMB 1.66 billion in the same period of 2023[16] Cash Flow and Liquidity - Net cash flow from operating activities for the third quarter was a negative RMB 33.61 million, a 61.58% decrease year-over-year, and year-to-date net cash flow from operating activities was a negative RMB 92.83 million, a 386.33% decrease[2] - Net cash flow from operating activities was negative RMB 92.83 million in the first three quarters of 2024, compared to negative RMB 19.09 million in the same period of 2023[19] - Cash received from investments was RMB 694.80 million in the first three quarters of 2024, compared to RMB 1.55 billion in the same period of 2023[19] - Net cash flow from investing activities was RMB 70.05 million in the first three quarters of 2024, compared to negative RMB 587.10 million in the same period of 2023[20] - Cash paid for the construction of fixed assets, intangible assets, and other long-term assets was RMB 41.28 million in the first three quarters of 2024, compared to RMB 143.55 million in the same period of 2023[20] - Net cash flow from financing activities was negative RMB 51.27 million in the first three quarters of 2024, compared to negative RMB 50.09 million in the same period of 2023[20] - The net increase in cash and cash equivalents was negative RMB 74.43 million in the first three quarters of 2024, compared to negative RMB 654.85 million in the same period of 2023[20] - The ending balance of cash and cash equivalents was RMB 272.81 million as of September 2024, compared to RMB 376.69 million as of September 2023[20] Earnings and Shareholder Metrics - Basic earnings per share for the third quarter was a loss of RMB 0.41, a 57.69% decrease year-over-year, and year-to-date basic earnings per share was a loss of RMB 0.86, a 138.89% decrease[2] - Basic earnings per share for the first three quarters of 2024 were RMB -0.86, compared to RMB -0.36 in the same period of 2023[18] - Weighted average return on equity for the third quarter was -2.92%, a decrease of 1.45 percentage points year-over-year, and year-to-date weighted average return on equity was -5.97%, a decrease of 3.94 percentage points[2] - The total number of ordinary shareholders at the end of the reporting period is 3,784[11] Shareholder Structure - Beijing Kangwei Century Biotechnology Co., Ltd. holds 50,400,000 shares, accounting for 44.80% of the total shares[11] - Taizhou Kangwei Co-Creation Enterprise Management Consulting Partnership holds 21,600,000 shares, accounting for 19.20% of the total shares[11] - The Industrial and Commercial Bank of China Limited - Rongtong Health Industry Flexible Allocation Mixed Securities Investment Fund holds 2,850,000 shares, accounting for 2.53% of the total shares[11] - Jiangsu Kangwei Century Biotechnology Co., Ltd. repurchase special securities account holds 2,388,091 shares, accounting for 2.12% of the total shares[11] - CITIC Securities - CITIC Bank - CITIC Securities Kangwei Century Employee Participation in Sci-Tech Innovation Board Strategic Placement Collective Asset Management Plan holds 1,708,891 shares, accounting for 1.52% of the total shares[11] - Mao Aiying holds 1,577,087 shares, accounting for 1.40% of the total shares[11] - Jiangsu Yida Achievement Innovation and Venture Investment Fund holds 1,506,000 shares, accounting for 1.34% of the total shares[11] - Taizhou Transformation and Upgrading Industrial Investment Fund holds 1,500,000 shares, accounting for 1.33% of the total shares[11] - CITIC Securities Investment Co., Ltd. holds 1,117,933 shares, accounting for 0.99% of the total shares[11] Expenses and Other Financial Metrics - Sales expenses for the first three quarters of 2024 increased to RMB 57.05 million, up 6.9% from RMB 53.35 million in the same period of 2023[17] - Financial expenses for the first three quarters of 2024 were RMB -4.29 million, compared to RMB -9.21 million in the same period of 2023[17] - Other comprehensive income for the first three quarters of 2024 was RMB 5,959.49, a significant decrease from RMB 617,428.47 in the same period of 2023[18] - Sales of goods and services received cash of RMB 90.53 million in the first three quarters of 2024, compared to RMB 174.58 million in the same period of 2023[19]

2024 年半年度报告 公司代码：688426 公司简称：康为世纪 江苏康为世纪生物科技股份有限公司 2024 年半年度报告 二○二四年八月 1 / 207 2024 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"五、风险因素"中说明了可能对公司产生重 大不利影响的风险因素，敬请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人王春香、主管会计工作负责人郝超峰及会计机构负责人（会计主管人员）包小菁 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、经营计划、发展战略等前瞻性陈述，不构成公司对投资者的 实质承诺，请投资者注意投资风险。 九、 是否存在被 ...

康为世纪（688426） 买入（维持） | --- | --- | --- | --- | --- | --- | |------------------------------|--------|----------|---------|--------|----------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 521.60 | 171.34 | 242.79 | 354.98 | 499.00 | | 同比（ % ） | 54.11 | (67.15) | 41.70 | 46.21 | 40.57 | | 归母净利润（百万元） | 159.26 | (84.41) | (69.53) | 5.23 | 109.57 | | 同比（ % ） | 26.55 | (153.00) | 17.62 | 107.52 | 1,994.22 | | EPS- 最新摊薄（元 / 股） | 1.42 | (0.75) | (0.62) | 0.05 | 0.97 | | P/E （现价 & 最新 ...

2024年第一季度报告 证券代码：688426 证券简称：康为世纪 江苏康为世纪生物科技股份有限公司 2024 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 审计师发表非标意见的事项 □适用 √不适用 一、 主要财务数据 ...

2023年年度报告 公司代码：688426 公司简称：康为世纪 江苏康为世纪生物科技股份有限公司 2023 年年度报告 ...

证券研究报告·公司深度研究·生物制品 1. 康为世纪：深耕分子检测行业，布局试剂及服务一体化 数据来源：《2022 年全国癌症报告》，东吴证券研究所 数据来源：《Journal of Gastroenterology and Hepatology》，东吴证券研究所 Hp 感染是慢性活动性胃炎、消化性溃疡、胃黏膜相关淋巴组织的淋巴瘤和胃癌的 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|------------|-------|------------|-------|--------|-------|-------|-------------------------------|-------|---------------------------------------|-------| | 100% | | | 77.2% | 72.3% | | | | 100% | 6% | 10% | 15% | | | 80% | 67.2% | 67.7% | | | ...

2023 年第三季度报告 证券代码：688426 证券简称：康为世纪 江苏康为世纪生物科技股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 单位:元 币种: 人民币 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期末 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | | | 同期增减变 | | | | 动幅度(%) | | 动幅度(%) | | 营业收入 | 29,896,120.36 | -77.42 | 151,454, ...

2023年半年度报告 公司代码：688426 公司简称：康为世纪 江苏康为世纪生物科技股份有限公司 2023 年半年度报告 ...

2023年第一季度报告 证券代码：688426 证券简称：康为世纪 江苏康为世纪生物科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 ...